These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33025257)

  • 1. Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.
    Pöhlmann J; Norrbacka K; Boye KS; Valentine WJ; Sapin H
    Eur J Health Econ; 2020 Nov; 21(8):1179-1196. PubMed ID: 33025257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
    Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
    Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database.
    Špacírová Z; Epstein D; Espín J
    Eur J Health Econ; 2022 Dec; 23(9):1563-1575. PubMed ID: 35217963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
    Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool.
    Perrier L; Buja A; Mastrangelo G; Baron PS; Ducimetière F; Pauwels PJ; Rossi CR; Gilly FN; Martin A; Favier B; Farsi F; Laramas M; Baldo V; Collard O; Cellier D; Blay JY; Ray-Coquard I
    BMC Health Serv Res; 2014 Nov; 14():537. PubMed ID: 25399725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating retinal vein occlusions in France, Germany, and Italy: an analysis of treatment patterns, resource consumption, and costs.
    Augustin AJ; Sahel JA; Cerulli L; Texier-Richard B; Buchholz PM; Kobelt G
    Eur J Ophthalmol; 2012; 22(5):776-84. PubMed ID: 22729442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies.
    Stegbauer C; Falivena C; Moreno A; Hentschel A; Rosenmöller M; Heise T; Szecsenyi J; Schliess F
    BMC Health Serv Res; 2020 Nov; 20(1):1043. PubMed ID: 33198734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries.
    Badia JM; Casey AL; Petrosillo N; Hudson PM; Mitchell SA; Crosby C
    J Hosp Infect; 2017 May; 96(1):1-15. PubMed ID: 28410761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.
    Le Pen C; Bauduceau B; Ansolabehere X; Troubat A; Bineau S; Ripert M; Dejager S
    Ann Endocrinol (Paris); 2021 Apr; 82(2):99-106. PubMed ID: 33417963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unit Costs in Health Economic Evaluations: Quo Vadis, Austria?
    Mayer S; Łaszewska A; Simon J
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review.
    Kip MMA; Currie G; Marshall DA; Grazziotin Lago L; Twilt M; Vastert SJ; Swart JF; Wulffraat N; Yeung RSM; Benseler SM; IJzerman MJ;
    Pediatr Rheumatol Online J; 2019 May; 17(1):20. PubMed ID: 31060557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research.
    Am J Respir Crit Care Med; 2002 Feb; 165(4):540-50. PubMed ID: 11850349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
    Banz K; Bischoff H; Brunner M; Chouaid C; de Castro Carpeño J; de Marinis F; Grossi F; Vergnenègre A; Walzer S
    Lung Cancer; 2011 Dec; 74(3):529-34. PubMed ID: 21592611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
    Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
    Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, England.
    Clarke CS; Vindrola-Padros C; Levermore C; Ramsay AIG; Black GB; Pritchard-Jones K; Hines J; Smith G; Bex A; Mughal M; Shackley D; Melnychuk M; Morris S; Fulop NJ; Hunter RM
    Appl Health Econ Health Policy; 2021 Nov; 19(6):797-810. PubMed ID: 34009523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.